SCHEMBL31093748

SCHEMBL31093748

Cc1cc(N)c(Br)nc1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ TSHR P16473 3/20 0.45
▸ ATP4A P20648 2/20 0.44
▸ ATP4B P51164 2/20 0.44
▸ MGMT P16455 4/20 0.44
▸ CYP3A4 P08684 2/20 0.44
▸ MPO P05164 2/20 0.44
▸ TPO P07202 1/20 0.44
▸ EPX P11678 1/20 0.44
▸ CDK1 P06493 2/20 0.43
▸ CCNB1 P14635 2/20 0.43
▸ CCNA2 P20248 2/20 0.43
▸ CDK2 P24941 2/20 0.43
▸ CCNA1 P78396 2/20 0.43
▸ NUDT1 P36639 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ STAT3 P40763 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ BAK1 Q16611 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18080647 0.77 L3MBTL1 (0.48) L3MBTL1TSHRATP4AATP4BHTT
SCHEMBL26971397 0.76 L3MBTL1 (0.58) L3MBTL1TSHRATP4AATP4BMGMT
SCHEMBL15053418 0.74 L3MBTL1 (0.47) L3MBTL1TSHRHTTSMN1; SMN2STAT3
SCHEMBL18049874 0.74 NUDT1 (0.55) L3MBTL1TSHRATP4AATP4BMGMT
SCHEMBL5648620 0.74 L3MBTL1 (0.47) L3MBTL1TSHRATP4AATP4BMGMT
SCHEMBL28485531 0.74 L3MBTL1 (0.64) L3MBTL1CYP3A4HTTSMN1; SMN2STAT3
SCHEMBL17597368 0.73 MGMT (0.46) L3MBTL1TSHRATP4AATP4BMGMT
SCHEMBL21497197 0.72 MGMT (0.50) L3MBTL1TSHRATP4AATP4BMGMT
SCHEMBL4644108 0.71 L3MBTL1 (0.55) L3MBTL1TSHRATP4AATP4BNUDT1
SCHEMBL27301730 0.71 L3MBTL1 (0.56) L3MBTL1TSHRATP4AATP4BMGMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2026-03-19 — — US disclosed
EP-4673436-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2026-01-07 — — EP disclosed
WO-2024179948-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2024-09-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078122-A1 INDAZOLE COMPOUNDS AS PKMYT1 KINASE INHIBITORS PKN3, PKMYT1, IP6K3 L3MBTL1 687/4885TSHR 2477/4885ATP4A 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback